Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for 89BIO (ETNB : NSDQ)

• Company Description    89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $2.64 Daily Weekly Monthly 20 Day Moving Average: 297,536 shares Shares Outstanding: 20.35 (millions) Market Capitalization: $53.73 (millions) Beta: 2.82 52 Week High: $23.07 52 Week Low: $2.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.33% 0.44% 12 Week -37.88% -32.60% Year To Date -79.80% -75.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 142 SANSOME STREET SECOND FLOOR - SAN FRANCISCO,CA 94104 USA ph: 415-432-9270 fax: - investors@89bio.com http://www.89bio.com

• General Corporate Information    Officers Rohan Palekar - Chief Executive Officer Ryan Martins - Chief Financial Officer Steven Altschuler - Director Derek DiRocco - Director Gregory Grunberg - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 282559103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 20.35 Most Recent Split Date: (:1) Beta: 2.82 Market Capitalization: $53.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.52 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -70.27% vs. Previous Quarter: 3.08% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -73.63 12/31/21 - -56.71 09/30/21 - -42.89 ROA 03/31/22 - -62.29 12/31/21 - -50.71 09/30/21 - -40.24 Current Ratio 03/31/22 - 7.36 12/31/21 - 8.29 09/30/21 - 8.42 Quick Ratio 03/31/22 - 7.36 12/31/21 - 8.29 09/30/21 - 8.42 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 5.05 12/31/21 - 6.21 09/30/21 - 7.31 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.14 12/31/21 - 0.13 09/30/21 - 0.01 Debt-to-Capital 03/31/22 - 12.35 12/31/21 - 11.83 09/30/21 - 0.97

Powered by Zacks Investment Research ©